Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06756074 | Reinforced Pancreaticojejunostomy With or Without glubran2 | recruiting | Phase 2 | 100 | Minia UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | recruiting | Phase 2 | 88 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06151223 | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer | recruiting | — | 5,000 | Mayo ClinicOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06821503 | Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C | recruiting | Phase 1 / Phase 2 | 72 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00830557 | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | recruiting | — | 20,000 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07254091 | Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer | recruiting | Early Phase 1 | 10 | Northwell HealthOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00899626 | Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients | recruiting | — | 5,000 | Vanderbilt University Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04683315 | PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples(PANCREAS) | recruiting | Phase 2 | 84 | Medical College of WisconsinOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05052671 | ctDNA Assay in Patients With Resectable Pancreatic Cancer(OU-SCC-ctDNA) | recruiting | — | 50 | University of OklahomaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06953999 | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | recruiting | Phase 3 | 999 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07114315 | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer | recruiting | Phase 2 | 160 | AkesoINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04473794 | Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts | recruiting | — | 5,000 | Johns Hopkins UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04485286 | Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury | recruiting | Phase 2 | 72 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04588025 | Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response | recruiting | N/A | 55 | Ohio State UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07006077 | Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer | recruiting | Phase 2 | 12 | Hangzhou Converd Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07049055 | A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer(Carolyn-USA) | recruiting | Phase 1 / Phase 2 | 144 | Engeneic Pty LimitedINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439757 | AI-Powered Precision Decision-Making for Pancreatic Diseases | recruiting | — | 2,000 | Changhai HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07425483 | CAR-NK Cells (CL-NK-003) in Pancreatic Cancer | recruiting | Phase 1 | 9 | Changhai HospitalOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05356117 | Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial | recruiting | N/A | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07124611 | A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer | recruiting | N/A | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416240 | Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. | recruiting | Early Phase 1 | 10 | Hainan Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06906562 | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | recruiting | Phase 2 | 40 | Sameek RoychowdhuryOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407231 | Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC) | recruiting | N/A | 18 | Institute of Oncology LjubljanaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06353646 | XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer | recruiting | N/A | 28 | Wu WenmingOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06384560 | Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)(PREOPANC-5) | recruiting | Phase 1 / Phase 2 | 66 | Amsterdam UMC, location VUmcOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07240766 | HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation | recruiting | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02775461 | Pancreas Registry and High Risk Registry | recruiting | — | 1,368 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07326137 | A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain | recruiting | — | 103 | Tongji HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02393703 | Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer | recruiting | — | 181 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06662006 | Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients | recruiting | Phase 2 | 56 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT02478892 | Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk | recruiting | — | 200 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07236177 | B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.(B-GLUCANCER2) | recruiting | Early Phase 1 | 220 | Poitiers University HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer(CATIQ P3) | recruiting | Phase 3 | 480 | Quercis Pharma AGINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07030283 | Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | recruiting | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells(SHARON) | recruiting | Phase 1 | 24 | General Oncology, Inc.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07249775 | A First-in-Human Study of FID-022 in Solid Tumor Patients | recruiting | — | 120 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06951997 | QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer | recruiting | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07312422 | LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study | recruiting | Phase 1 / Phase 2 | 10 | Zhejiang Provincial People's HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2026source: clinicaltrials